The dramatic growth of a key federal drug discount program has fueled debate about whether it is helping low-income patients as intended or primarily benefiting health care providers.

AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.

On its 20th birthday, a group of prominent healthcare leaders have launched a campaign to rejuvenate the image of the 340B drug discount program. The program allows nonprofit hospitals, as well as ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. In Maine, the 340B drug program was meant to be a structure of care — a ...

The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s law protecting 340B pricing for contract ...

For Michigan families like mine, access to life-saving medications isn’t just a policy debate — it’s a matter of survival. When my daughters were diagnosed with cystic fibrosis (CF), my world shifted ...

Well-intentioned programs often get turned on their heads inside the Capital Beltway. The 340B drug pricing program, designed to lower the cost of certain medications for hospitals and clinics, is a ...

As a permanent ostomate, I am all too familiar with the complexities of the American healthcare system. I’ve been insured, underinsured, and uninsured, often forced to ration medications and avoid ...